These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
133 related items for PubMed ID: 6431809
21. Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis. Bouillon R, Verberckmoes R, Moor PD. Kidney Int; 1975 Jun; 7(6):422-32. PubMed ID: 169419 [Abstract] [Full Text] [Related]
22. Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (calcitriol) therapy. Bellazzi R, Romanini D, Bacchella L, Nai M, Aprile C, Santagostino M, De Vincenzi A. Nephron; 1991 Jun; 57(3):273-82. PubMed ID: 2017266 [Abstract] [Full Text] [Related]
23. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder. Cheng IK, Lu HB, Chan CY, Cheng SW, Robinson JD, Tam SC, Lo WK, Cheung WC. Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365 [Abstract] [Full Text] [Related]
24. Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium. Nilsson P, Johansson SG, Danielson BG. Nephron; 1984 Aug; 37(1):25-9. PubMed ID: 6717701 [Abstract] [Full Text] [Related]
25. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L. Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [Abstract] [Full Text] [Related]
26. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D. Teruel JL, Nitvarro JF, Marcen R, Aguilera A, Tato A, Ottuño J. Miner Electrolyte Metab; 1997 Nov; 23(1):19-24. PubMed ID: 9058365 [Abstract] [Full Text] [Related]
27. Effect of dialysate calcium concentration on plasma parathyroid hormone during hemodialysis. McIntosh CH, Fuchs C, Dorn D, Quellhorst E, Henning HV, Hesch RD, Scheler F. Nephron; 1977 Nov; 19(2):88-94. PubMed ID: 887190 [Abstract] [Full Text] [Related]
28. Lack of influence of recombinant human erythropoietin on parathyroid function in hemodialysis patients with secondary hyperparathyroidism. Lai YH, Tsai JC, Chen HC, Guh JY, Hwang SJ, Tsai JH. Nephron; 1995 Nov; 70(2):223-8. PubMed ID: 7566308 [Abstract] [Full Text] [Related]
29. Is aluminum toxicity responsible for uremic pruritus in chronic hemodialysis patients? Friga V, Linos A, Linos DA. Nephron; 1997 Nov; 75(1):48-53. PubMed ID: 9031270 [Abstract] [Full Text] [Related]
30. Effects of Lowering Dialysate Calcium Concentration on Bone Metabolic Markers in Hemodialysis Patients With Suppressed Serum Parathyroid Hormone: A Preliminary Study. Niwa H, Fukasawa H, Ishibuchi K, Kaneko M, Yasuda H, Furuya R. Ther Apher Dial; 2018 Oct; 22(5):503-508. PubMed ID: 29923680 [Abstract] [Full Text] [Related]
31. [Parathyroid function in patients on chronic intermittent hemodialysis (author's transl)]. Augustin R, Hackeng WH. Klin Wochenschr; 1977 Aug 15; 55(16):811-6. PubMed ID: 409876 [Abstract] [Full Text] [Related]
32. Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients. Hwang JC, Chen CA, Wang CT, Chen HC. Ren Fail; 2008 Aug 15; 30(10):943-51. PubMed ID: 19016144 [Abstract] [Full Text] [Related]
33. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V. Lancet; 1986 Apr 19; 1(8486):880-2. PubMed ID: 2870354 [Abstract] [Full Text] [Related]
34. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients. Fiedler R, Deuber HJ, Langer T, Osten B, Mohan S, Jehle PM. Nephron Clin Pract; 2004 Apr 19; 96(1):c3-9. PubMed ID: 14752247 [Abstract] [Full Text] [Related]
35. Bone aluminum and histomorphometric features of renal osteodystrophy. Hodsman AB, Sherrard DJ, Alfrey AC, Ott S, Brickman AS, Miller NL, Maloney NA, Coburn JW. J Clin Endocrinol Metab; 1982 Mar 19; 54(3):539-46. PubMed ID: 7056841 [Abstract] [Full Text] [Related]
36. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. Andress DL, Maloney NA, Endres DB, Sherrard DJ. J Bone Miner Res; 1986 Oct 19; 1(5):391-8. PubMed ID: 3503554 [Abstract] [Full Text] [Related]
37. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J. Nephron; 1985 Oct 19; 39(4):309-15. PubMed ID: 3982576 [Abstract] [Full Text] [Related]
38. Serum ionized calcium, parathyroid hormone and phosphate in uremic patients during and between hemodialysis. Rudnicki M, Frølich A, Haaber A, Tvedegaard E, Thode J. Clin Nephrol; 1993 Oct 19; 40(4):225-9. PubMed ID: 8261680 [Abstract] [Full Text] [Related]
39. Control of parathyroid function in patients with a short history of hemodialysis. Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M. Ther Apher Dial; 2005 Feb 19; 9(1):39-43. PubMed ID: 15828904 [Abstract] [Full Text] [Related]
40. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L. Yamada S, Ueki K, Tokumoto M, Suehiro T, Kimura H, Taniguchi M, Fujimi S, Kitazono T, Tsuruya K. Ther Apher Dial; 2016 Feb 19; 20(1):31-9. PubMed ID: 26482334 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]